gemcitabine

(redirected from Gemzar)
Also found in: Medical.

gem·cit·a·bine

(jĕm-sī′tə-bēn′)
n.
A nucleoside analog, C9H11F2N3O4, used in its hydrochloride form in the treatment of pancreatic cancer and in combination with other drugs to treat breast, ovarian, and non-small cell lung cancer.

[gem-, perhaps shortening and alteration of CCRF-CEM, designation of the leukemia cell culture on which it was first tested + -citabine, nucleoside analog antiviral and anticancer drug suffix; see zalcitabine.]
References in periodicals archive ?
Initiate Phase 1 safety dose-escalation in combination with AB122, gemcitabine (Gemzar) and nab-paclitaxel (Abraxane) in patients with first-line metastatic pancreatic cancer.
Drug Brand Names Carbamazepine * Carbatrol, Gemcitabine injection Tegretol * Gemzar Carboplatin * Paraplatin Lithium * Eskalith, Lithobid Divalproex sodium * Olanzapine * Zyprexa Depakote Paditaxel injection Doxorubicin liposome * Abraxane injection * Doxil Quetiapine * Seroquel Bottom Line
The top five global brands that are commercially available in the market are Avastin, Tarceva, Alimta, Gemzar and Taxotere.
Bloss has held many leadership roles and has been responsible for the development, approval and commercialization of over ten successful oncology drugs including Gemzar, Tarceva, Sorafenib, Tykerb, Xtandi and others.
After an average three years of follow-up, almost 40 percent of the folfirinox patients were disease-free compared with about 20 percent who had the standard drug, Gemzar. Overall, almost two-thirds of folfirinox patients were still alive compared with almost half of Gemzar patients, unexpectedly good results, said Dr.
During the patient's hospitalization, GEMZAR CYSPLATINE-type chemotherapy was set up after the multidisciplinary consultation meeting.
Patients will be treated with two existing chemotherapies, nab-paclitaxel (Abraxane) and gemcitabine (Gemzar), in combination with a new treatment called PEGPH20, an enzyme which breaks down a chemical called HA which the tumour feeds off.
Many companies in the past have tried to use two, sometimes three, immunotherapies for pancreatic cancer, but have not produced favorable results since Gemcitabine (Gemzar) was approved in 1996 for pancreatic cancer.
The global breast cancer therapeutics market report estimates the market size (Revenue USD million - 2013 to 2020) for key market segments based on the drug classes - brand name (chemical name) such as antimetabolites - Gemzar (gemcitabine), aromatase inhibitors - Afinitor (everolimus), Arimidex (anastrozole), Aromasin (exemestane), Femara (leterozole), Ibrance (palbociclib); Her2 Inhibitors - Herceptin (trastuzumab), Kadcyla (ado-trastuzumab emtansine), Perjeta (pertuzumab), Tykerb (lapatinib); Hormone receptors - Fareston, Faslodex, Zoladex; and Mitotic inhibitors - Halaven (eribulin), Ixempra (ixabepilone), Taxotere (docetaxel), and forecasts growth trends (CAGR% - 2016 to 2020).
It will market a dozen oncology products including generic versions of Gemzar, Taxotere, Campostar and Zometa.
She was then treated with FOLFOX and was switched to Gemzar and Abraxane thereafter.